Personal information

Websites & social links

LinkedIn

Activities

Collapse all

Employment (1)

CIMA-Universidad de Navarra: Pamplona, Navarra, ES

2023-12-16 to present | Post-doctoral researcher (Solid Tumors Program)
Employment
Source: Self-asserted source
Iker Ausejo Mauleón

Works (8)

Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models

JCI Insight
2024-09-24 | Journal article
DOI: 10.1172/jci.insight.175257
Contributors: Iker Ausejo-Mauleon; Naiara Martinez-Velez; Andrea Lacalle; Daniel de la Nava; Javier Cebollero; Helena Villanueva; Noelia Casares; Javier Marco-Sanz; Virginia Laspidea; Oren Becher et al.
Source: check_circle
Crossref

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

Neuro-Oncology
2024-08-05 | Journal article
DOI: 10.1093/neuonc/noae066
Contributors: Daniel de la Nava; Iker Ausejo-Mauleon; Virginia Laspidea; Marisol Gonzalez-Huarriz; Andrea Lacalle; Noelia Casares; Marta Zalacain; Lucía Marrodan; Marc García-Moure; Maria C Ochoa et al.
Source: check_circle
Crossref

Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry

STAR Protocols
2024-03 | Journal article
DOI: 10.1016/j.xpro.2023.102803
Contributors: Iker Ausejo-Mauleon; Sara Labiano; Marta M. Alonso
Source: check_circle
Crossref

The rise of TIM‐3: A promising immune target in diffuse midline gliomas

Clinical and Translational Medicine
2024-01 | Journal article
DOI: 10.1002/ctm2.1536
Part of ISSN: 2001-1326
Part of ISSN: 2001-1326
Contributors: Iker Ausejo Mauleón; Sara Nuin; Marta M. Alonso
Source: Self-asserted source
Iker Ausejo Mauleón

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

Cancer Cell
2023-11 | Journal article
DOI: 10.1016/j.ccell.2023.09.001
Part of ISSN: 1535-6108
Contributors: Iker Ausejo-Mauleon; Sara Labiano; Daniel de la Nava; Virginia Laspidea; Marta Zalacain; Lucía Marrodán; Marc García-Moure; Marisol González-Huarriz; Irati Hervás-Corpión; Laasya Dhandapani et al.
Source: Self-asserted source
Iker Ausejo Mauleón

Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

Molecular Therapy - Oncolytics
2022-09 | Journal article
DOI: 10.1016/j.omto.2022.07.004
Part of ISSN: 2372-7705
Contributors: Guillermo Herrador-Cañete; Marta Zalacain; Sara Labiano; Virginia Laspidea; Montserrat Puigdelloses; Lucía Marrodan; Marc Garcia-Moure; Marisol Gonzalez-Huarriz; Javier Marco-Sanz; Iker Ausejo-Mauleon et al.
Source: Self-asserted source
Iker Ausejo Mauleón

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

JCI Insight
2022-04-08 | Journal article
DOI: 10.1172/jci.insight.154812
Contributors: Virginia Laspidea; Montserrat Puigdelloses; Sara Labiano; Lucía Marrodán; Marc Garcia-Moure; Marta Zalacain; Marisol Gonzalez-Huarriz; Naiara Martínez-Vélez; Iker Ausejo-Mauleon; Daniel de la Nava et al.
Source: check_circle
Crossref

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory

Molecular Cancer Therapeutics
2022-03-01 | Journal article
DOI: 10.1158/1535-7163.mct-21-0565
Part of ISSN: 1535-7163
Part of ISSN: 1538-8514
Contributors: Naiara Martinez-Velez; Virginia Laspidea; Marta Zalacain; Sara Labiano; Marc Garcia-Moure; Montse Puigdelloses; Lucía Marrodan; marisol gonzalez-huarriz; Guillermo Herrador-Cañete; Daniel de la Nava et al.
Source: Self-asserted source
Iker Ausejo Mauleón

Peer review (1 review for 1 publication/grant)

Review activity for The oncologist. (1)
How many people are using ORCID?